40,000 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Integral Health Asset Management LLC

Integral Health Asset Management LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 40,000 shares of the life sciences company's stock, valued at approximately $5,345,000.

Other large investors also recently bought and sold shares of the company. Tidal Investments LLC grew its stake in shares of Illumina by 38.0% during the 3rd quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company's stock valued at $580,000 after purchasing an additional 1,226 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Illumina by 2.2% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 18,170 shares of the life sciences company's stock valued at $2,369,000 after buying an additional 394 shares in the last quarter. Green Alpha Advisors LLC lifted its position in shares of Illumina by 82.9% during the 4th quarter. Green Alpha Advisors LLC now owns 4,693 shares of the life sciences company's stock valued at $627,000 after buying an additional 2,127 shares in the last quarter. CCLA Investment Management lifted its position in shares of Illumina by 20.5% during the 4th quarter. CCLA Investment Management now owns 535,050 shares of the life sciences company's stock valued at $71,493,000 after buying an additional 91,122 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Illumina by 5.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 42,748 shares of the life sciences company's stock valued at $5,712,000 after buying an additional 2,338 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Illumina

In other news, CFO Ankur Dhingra bought 6,100 shares of the stock in a transaction on Monday, May 12th. The stock was acquired at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares of the company's stock, valued at $2,022,616.26. This represents a 32.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.17% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ILMN shares. Piper Sandler lowered their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research report on Thursday. Robert W. Baird lowered their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. Citigroup lowered their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Guggenheim lowered their price target on Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $130.70.

Illumina Trading Up 3.4%

Illumina stock traded up $2.72 during mid-day trading on Friday, hitting $83.62. The company's stock had a trading volume of 2,338,618 shares, compared to its average volume of 2,316,765. The company has a 50 day moving average of $78.48 and a 200-day moving average of $111.12. The stock has a market cap of $13.23 billion, a PE ratio of -10.89, a P/E/G ratio of 1.60 and a beta of 1.35. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.96 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Illumina's quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.98 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.